| 130 | 1 | 165 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探讨磺达肝癸钠在骨科大手术围术期抗纤溶药序贯抗凝治疗中的有效性及安全性。方法 将2020年1月至2021年12月收治的拟行骨科大手术治疗的患者89例随机分为对照组（n=44）和试验组（n=45）。2组患者均采用抗纤溶药（氨甲环酸）序贯抗凝治疗（对照组予依诺肝素钠，试验组予磺达肝癸钠）。观察2组患者静脉血栓栓塞发生率、死亡率、总失血量、血红蛋白、血小板计数、凝血功能变化趋势和大出血事件发生率。结果 对照组和试验组的总失血量分别为（269.34±240.79） mL和（231.84±119.77）mL(P>0.05)。2组的血红蛋白和血小板计数在术前和术后第1、2、3、7、14天差异均无统计学意义（P>0.05）。术后第3天，试验组的凝血酶原时间显著长于对照组（P <0.05）；术后第7天，试验组的部分活化凝血酶原时间显著长于对照组（P <0.05）。2组均未发生下肢深静脉血栓和肺血栓栓塞症。结论 骨科大手术围术期将磺达肝癸钠应用于抗纤溶药序贯抗凝治疗是安全有效的，值得推荐。
Abstract：AIM To investigate the efficacy and safety of fondaparinux in perioperative anticoagulation therapy in patients undergoing major orthopedic surgery. METHODS From January 2020 to December 2021, 89 patients who underwent major orthopedic surgery were randomly divided into control group(n=44) and experiment group(n=45).Patients in both groups received antifibrinolytic medication(tranexamic acid) followed by sequential anticoagulant therapy(the control group was given enoxaparin, while the experiment group was given fondaparinux). The incidence of venous thromboembolism(VTE), mortality, total blood loss, changes in hemoglobin(Hb), platelet count(PLT), coagulation function, and incidence of major bleeding events were observed. RESULTS The total blood loss between the control group and experiment group was(269.34±240.79) mL and(231.84±119.77) mL, respectively. There were no statistically significant differences in Hb and PLT in the control group and experiment group on preoperative and postoperative days 1, 2, 3, 7, and 14(P > 0.05). The prothrombin time(PT) of experiment group was significantly longer than that of control group at 3 days after operation(P < 0.05). At 7 days after surgery, the activated partial thromboplastin time(APTT) of experiment group was significantly longer than that of control group(P < 0.05). Neither group experienced deep vein thrombosis or pulmonary thromboembolism. CONCLUSION It is safe and effective to apply fondaparinux to sequential anticoagulant therapy of antifibrinolytic agents during perioperative period of major orthopedic surgery, which is worthy of recommendation.
[1]中华护理学会糖尿病专业委员会.高血糖患者围手术期血糖护理工作指引[J].中华护理杂志, 2017, 52(7):794
[2]夏云芳,徐晶晶,秦瑶.糖尿病患者围术期血糖监测情况调查与分析[J].中华现代护理杂志, 2018, 24(15):1814.
[3] FRISCH A, CHANDRA P, SMILEY D, et al. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery[J]. Diabetes Care, 2010, 33(8):1783.
[4]中华医学会骨科学分会.中国骨科大手术静脉血栓栓塞症预防指南[J].中华骨科杂志, 2016,36(2):65.
[5]赵东风,张泳照,王俊生,等.围手术期应用氨甲环酸对骨科大手术失血量的影响[J].中国实用医药, 2020, 15(34):113.
[6] GROSS J B. Estimating allowable blood loss:corrected for dilution[J]. Anesthesiology, 1983, 58(3):277.
[7] TAN J X, CHEN H, LIU Q, et al. A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty[J]. J Surg Res, 2013, 184(2):880.
[8] CHEN Z Y, GAO Y, CHEN W, et al. Reduced blood loss after intraarticular tranexamic acid injection during total knee arthroplasty:a meta-analysis of the literature[J]. Knee Surg Sports Traumatol Arthrosc, 2014, 22(12):3181.
[9] HILL J, TREASURE T, National Clinical Guideline Centre for Acute and Chronic Conditions. Reducing the risk of venous thromboembolism in patients admitted to hospital:summary of NICE guidance[J]. BMJ, 2010, 340:c95.
[10] RANDELLI F, BIGGI F, DELLA ROCCA G, et al. Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery[J].J Orthop Traumatol, 2011, 12(1):69.
[11] K H O K H A R A, C H A R I A, M U R R AY D, e t a l. Ve n o u s thromboembolism and its prophylaxis in elective knee arthroplasty:an international perspective[J]. Knee, 2013, 20(3):170.
[12] LIN P C, HSU C H, CHEN W S, et al. Does tranexamic acid save blood in minimally invasive total knee arthroplasty?[J]. Clin Orthop Relat Res, 2011, 469(7):1995.
[13]胡旭栋,裴福兴,沈彬,等.氨甲环酸减少全膝关节置换术失血量的有效性和安全性评价[J].中国骨与关节外科, 2013, 6(Suppl 1):52.
[14] GEORGIADIS A G, MUH S J, SILVERTON C D, et al. A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty[J]. J Arthroplasty,2013, 28(Suppl 8):78.
[15] GILLETTE B P, DESIMONE L J, TROUSDALE R T, et al. Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty[J]. Clin Orthop Relat Res, 2013, 471(1):150.
[16]胡旭栋,周宗科,裴福兴,等.全膝关节置换术应用氨甲环酸后序贯应用阿哌沙班预防静脉血栓栓塞症的有效性和安全性[J].中华骨与关节外科杂志, 2015, 8(5):385.
[17]徐勇,柏光泽,李雷,等.磺达肝癸钠联合瘀血痹片预防全膝关节置换术后下肢深静脉血栓栓塞症的临床研究[J].中国医药科学,2022, 12(7):98.
[18]刘春,吴斗,胡俊江,等.利伐沙班磺达肝癸钠依诺肝素在关节置换术后预防静脉血栓栓塞症的回顾性研究[J].中国药物与临床,2014, 14(3):352.
[19]李虎,王健,肖军,等.比较磺达肝癸钠与依诺肝素预防骨科大手术后静脉血栓栓塞症疗效与安全性的Meta分析[J].南方医科大学学报, 2013, 33(3):370.
[20]杨晓娜,赵良虎,黄金,等.依诺肝素钠与磺达肝癸钠预防膝关节置换术后深静脉血栓的对比研究[J].中国医院用药评价与分析,2021, 21(10):1176.
[21] SHAIKH N. Heparin-induced thrombocytopenia[J]. J Emerg Trauma Shock, 2011, 4(1):97.
基本信息:
DOI：10.19577/j.1007-4406.2024.10.010
中图分类号:R969.3
引用信息:
[1]黄歆,徐磊,谢威,等.磺达肝癸钠在骨科大手术围术期抗纤溶药序贯抗凝治疗中的临床研究[J].中国临床药学杂志,2024,33(10):769-773.DOI:10.19577/j.1007-4406.2024.10.010.
基金信息:
四川省医学会静脉血栓栓塞症防治（恒瑞）专项科研课题（编号2019HR23）
2024-10-25
2024-10-25